Vanda Pharmaceuticals, headquartered in Washington, D.C., develops therapies for unmet medical needs and has three commercial products, including HETLIOZ and Fanapt. The company also has multiple drugs in development.
Vanda Pharmaceuticals (VNDA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Vanda Pharmaceuticals's actual EPS was -$0.46, missing the estimate of -$0.36 per share, resulting in a -26.44% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
